Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

Core Viewpoint - Novonesis reported strong organic sales growth of 11% and an adjusted EBITDA margin of 38.3% for the first quarter of 2025, maintaining its full-year outlook despite currency headwinds [1][6]. Sales Performance - The company experienced broad-based sales growth across regions and industries, with emerging markets growing by 15% and developed markets by 9% [1][5]. - In the Food & Health Biosolutions division, sales grew by 12%, with Food & Beverages increasing by 11% and Human Health achieving a 13% growth driven by Dietary Supplements [3]. - Planetary Health Biosolutions saw Household Care grow by 12% and Agriculture, Energy & Tech grow by 10% [4]. Regional Performance - Organic growth rates by geography for Q1 2025 were 14% in Europe, Middle East & Africa, 7% in North America, 9% in Asia Pacific, and 18% in Latin America [5]. Innovations and Product Launches - During the first three months, Novonesis launched six innovations, including an advanced protease portfolio aimed at efficient stain removal [2]. Financial Outlook - The company maintains its 2025 outlook of 5-8% organic sales growth (6-9% excluding exits from certain countries) and an adjusted EBITDA margin between 37-38% [6][7].